the efficacy and safety of Triticum aestivum L. sprout extract on improvement of Liver function

A 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Triticum aestivum L. sprout extract on improvement of Liver function

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007271

Enrollment

100

Registered

2022-05-12

Start date

2022-03-30

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Triticum aestivum extract group: once a day, 2 capsule once, before breakfast, for 8 weeks(700 mg/day, 500 mg/day for Triticum aestivum extract ) • Placebo group: once a day, 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Males and females aged 19-70 years at the screening examination 2) Participants with 46 (U/L)=Alanine Transaminase(ALT)=135 (U/L) 3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions.

Exclusion criteria

Exclusion criteria: 1)Patients with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 2)Patients who take medicine for improvement of liver function and intake health functional food within a month prior to the screening examination 3)Patients with a history of antipsychotic medication use within 3 months prior to the screening examination 4)Patients who have participated in other clinical trials within 3 months prior to the screening examination 5)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Design outcomes

Primary

Measure	Time frame
ALT(Alanine Transaminase);GGT(Gamma-glutamyl transferase)	—

Secondary

Measure	Time frame
liver function index;Lipids Metabolism index;steatosis index;Antioxidant index;inflammation index;Multidimensional Fatigue Scale	—

Countries

Korea, Republic of

Contacts

Public ContactSoo jung Park

Woosuk University Korean Medicine Medical Center

taorgi@hanmail.net+82-63-220-8676

Outcome results